Please login to the form below

Not currently logged in
Email:
Password:

vemurafenib

This page shows the latest vemurafenib news and features for those working in and with pharma, biotech and healthcare.

Novartis wins key adjuvant Taf/Mek approval in Europe

Novartis wins key adjuvant Taf/Mek approval in Europe

Taf/Mek competes directly with Roche's Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination in melanoma, but has been outselling its rival, particularly after Roche’s duo failed to hit the mark

Latest news

More from news
Approximately 3 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    For example, skin cancer patients who carry a BRAF V600 mutation are more likely to respond to BRAF inhibitors like Roche’s Zelboraf (Vemurafenib) than people without such mutations.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’ – ie

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    During this time, he was clinical lead for the development of Zelboraf (vemurafenib), which was co-developed by Roche and is predicted to reach peak-year sales of $1bn to

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics